Claim 70% Off TipRanks This Holiday Season
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Novo Nordisk ( (NVO) ) has issued an update.
On 22 December 2025, Novo Nordisk reported that the US Food and Drug Administration approved its once‑daily Wegovy pill (oral semaglutide 25 mg), the first oral GLP‑1 receptor agonist therapy cleared in the United States for weight management and for reducing the risk of major adverse cardiovascular events in adults with obesity or overweight and at least one weight‑related condition. The approval, backed by the phase 3 OASIS and SELECT trial programmes, showed mean weight loss of 16.6% in the OASIS 4 study—comparable to injectable Wegovy 2.4 mg—with one in three patients achieving at least 20% weight loss and a safety profile consistent with previous semaglutide data; Novo Nordisk plans a US launch in early January 2026 and has already filed for obesity indications with European and other regulators, reinforcing its leadership in the fast‑growing obesity and cardiometabolic market and expanding treatment options for patients who prefer an oral alternative to injections.
The most recent analyst rating on (NVO) stock is a Hold with a $46.00 price target. To see the full list of analyst forecasts on Novo Nordisk stock, see the NVO Stock Forecast page.
Spark’s Take on NVO Stock
According to Spark, TipRanks’ AI Analyst, NVO is a Outperform.
Novo Nordisk’s strong financial performance and reasonable valuation are key strengths, supporting a solid overall score. However, bearish technical indicators and challenges highlighted in the earnings call, such as market share loss and restructuring, weigh on the score. The company’s strategic focus on long-term growth and attractive dividend yield provide additional support.
To see Spark’s full report on NVO stock, click here.
More about Novo Nordisk
Novo Nordisk is a leading global healthcare company founded in 1923 and headquartered in Denmark, built on a long heritage in diabetes care and focused on defeating serious chronic diseases. The group pioneers GLP-1–based therapies and other innovative treatments, employs around 78,500 people in 80 countries, and markets its products in roughly 170 countries, with its B shares listed on Nasdaq Copenhagen and American depositary receipts trading on the New York Stock Exchange.
Average Trading Volume: 16,389,142
Technical Sentiment Signal: Sell
Current Market Cap: $216.9B
Find detailed analytics on NVO stock on TipRanks’ Stock Analysis page.